By Drug Target Review –
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
Chimeric antigen receptor (CAR) T-cell therapy, which uses a patient’s own immune cells to fight cancer, has been an effective treatment for lymphoma and other blood cancers. Yet adapting the therapy to solid tumours, which account for roughly 90 percent of all cases – eg, prostate, breast, lung and ovarian cancers – is still a huge challenge.
Now, researchers at the USC Norris Comprehensive Cancer Center, in collaboration with City of Hope, have developed a new solution. Their study, published in Nature Biomedical Engineering, demonstrates that genetically engineered CAR T cells can deliver a targeted, potent attack on solid tumours while avoiding harmful side effects.
